PerkinElmer, Inc., (NYSE: PKI) a global leader committed to innovating for a healthier world, today announced that the Company has completed its previously announced acquisition of Oxford Immunotec Global PLC (Oxford Immunotec). PerkinElmer originally announced its intent to acquire Oxford Immunotec on January 7, 2021. Headquartered in Abingdon, UK, Oxford Immunotec is recognized as a global leader of proprietary test kits for latent tuberculosis. Its Interferon Gamma Release Assay (IGRA) offering identifies individuals who are infected with tuberculosis.
Read the full article: PerkinElmer Completes Acquisition of Oxford Immunotec Global PLC //
Source: https://www.businesswire.com/news/home/20210309005100/en/PerkinElmer-Completes-Acquisition-of-Oxford-Immunotec-Global-PLC